KRAS and head and neck squamous cell carcinoma: These cell lines were selected as representative of tumor types for which radiotherapy is a curative treatment option in the clinic as well as the prevalence of common oncogenic molecular characteristics of relevance to HNSCC and radioresistance (EGF-R overexpression, HN5 and HN3; HPV status, HeLa; activated kRAS and PI3K catalytic subunit, HCT116).